HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indiana Ups State Power To Limit Pseudoephedrine Product Sales

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

DEA has the authority and expertise to conduct stress tests on pseudoephedrine formulations, says CHPA state government director Carol Gutierrez. But Indiana allows its pharmacy board to say whether a PSE product is tamper-resistant.

You may also be interested in...



Perrigo Deal Makes Extraction-Resistant PSE A Two-Player Competition

Via Highland Pharmaceuticals agreement, Perrigo snaps up the only tamper-resistant pseudoephedrine formulation still available for licensing. It now goes up against Bayer – but will beat the pharma giant to market.

Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation

Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.

To Curb PSE Diversion, Retailers Lead By Example With Emphasis On Tamper-Resistant Products

An HHS agency’s 2013 drug use survey shows the number of meth users rising by 155,000 after changing little the previous two years. Acura Pharmaceuticals notes the survey and Tennessee data showing that making only tamper-resistant, single-ingredient PSE products available affects the diversion rate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel